funny how interpretations can differ between people... i felt like PR was more highlighting the need for MPS to be first to make sure that OA wasn't priced against $17 NSAIDS...in this order it will instead be priced against (a minimum $2.5k - $6k USD) IPPS for MPS in the comparable product analysis... i.e. it is that order to ensure that our much larger addressable target market, OA, maximises revenue...
the above, as opposed to indicating higher pricing for MPS by it going first... it can't be tested against NSAIDS (my assumption) for comparable pricing.
Ann: Paradigm AGM Presentation, page-40
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $101.4M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 29.5¢ | 28.5¢ | $79.93K | 274.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12951 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 23984 | 3 |
View Market Depth
| Last trade - 16.10pm 08/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |